» Articles » PMID: 35467472

Inflammation-targeted Cannabidiol-loaded Nanomicelles for Enhanced Oral Mucositis Treatment

Overview
Journal Drug Deliv
Specialty Pharmacology
Date 2022 Apr 25
PMID 35467472
Authors
Affiliations
Soon will be listed here.
Abstract

One of the most common complications of cancer chemotherapy is oral mucositis (OM), a serious kind of oral ulceration, but its effective treatment remains a serious challenge. In this study, we used deoxycholic acid and fucoidan to prepare inflammation-targeting nanomicelles (FD), because fucoidan can target inflammation due to its high binding affinity for P-selectin. The hydrophobic anti-inflammatory drug cannabidiol (CBD) was then loaded into the hydrophobic core of FD. The resulting CBD-loaded FD micelles (CBD/FD) had uniform particle size and morphology, as well as favorable serum stability. Moreover, administration of the FD micelles intravenous injection or dripping in an OM mouse model enhanced the accumulation and retention of CBD. CBD/FD also showed a better anti-inflammatory effect compared to free CBD after local or systemic administration , while they accelerated OM healing and inhibited Ly6G inflammatory cell infiltration and NF-κB nuclear transcription. Our results show that CBD/FD nanomicelles are a promising agent for OM treatment.

Citing Articles

Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection.

de Brito Siqueira A, Cremasco P, Bahu J, Pioli da Silva A, Melo de Andrade L, Gonzalez P J Tradit Complement Med. 2023; 13(6):575-587.

PMID: 38020546 PMC: 10658372. DOI: 10.1016/j.jtcme.2023.08.006.


Relevance of the Extraction Stage on the Anti-Inflammatory Action of Fucoidans.

Florez-Fernandez N, Vaamonde-Garcia C, Torres M, Bujan M, Muinos A, Muinos A Pharmaceutics. 2023; 15(3).

PMID: 36986669 PMC: 10058023. DOI: 10.3390/pharmaceutics15030808.


Formulation of Nanomicelles Loaded with Cannabidiol as a Platform for Neuroprotective Therapy.

Yordanov Y, Stefanova D, Spassova I, Kovacheva D, Tzankova V, Konstantinov S Pharmaceutics. 2022; 14(12).

PMID: 36559117 PMC: 9781481. DOI: 10.3390/pharmaceutics14122625.


Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.

Huang J, Hwang A, Jia Y, Kim B, Iskandar M, Mohammed A Int J Mol Sci. 2022; 23(23).

PMID: 36499758 PMC: 9737148. DOI: 10.3390/ijms232315434.

References
1.
da Costa Cunha Mafra C, Vasconcelos R, de Medeiros C, Leitao R, Brito G, Costa D . Gliclazide Prevents 5-FU-Induced Oral Mucositis by Reducing Oxidative Stress, Inflammation, and P-Selectin Adhesion Molecules. Front Physiol. 2019; 10:327. PMC: 6445135. DOI: 10.3389/fphys.2019.00327. View

2.
Elad S, Yarom N . The Search for an Effective Therapy and Pain Relief for Oral Mucositis. JAMA. 2019; 321(15):1459-1461. DOI: 10.1001/jama.2019.3269. View

3.
Pulito C, Cristaudo A, La Porta C, Zapperi S, Blandino G, Morrone A . Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020; 39(1):210. PMC: 7542970. DOI: 10.1186/s13046-020-01715-7. View

4.
Cuba L, Salum F, Guimaraes F, Cherubini K, Borghetti R, de Figueiredo M . Cannabidiol on 5-FU-induced oral mucositis in mice. Oral Dis. 2020; 26(7):1483-1493. DOI: 10.1111/odi.13413. View

5.
Muthumalage T, Rahman I . Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts. Toxicol Appl Pharmacol. 2019; 382:114713. PMC: 6917034. DOI: 10.1016/j.taap.2019.114713. View